Re­gen­eron, Sanofi talk up po­ten­tial block­buster fran­chise as Dupix­ent sweeps in rhi­nos­i­nusi­tis PhI­II

A busy clin­i­cal team at Re­gen­eron $REGN and Sanofi $SNY has out­lined an­oth­er seg­ment on the al­ler­gic in­flam­ma­to­ry map that they plan to build their …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.